0000000000282236

AUTHOR

Francesco Saccà

showing 2 related works from this author

Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chro…

2016

Inflammatory activation plays a pivotal role in chronic heart failure (CHF) through the increased expression of pro-inflammatory cytokines [1]. Decreased plasma levels of Interleukin (IL-) 5, IL-7 and Interferon-γ (IFN-γ) and increased levels of IL-9 have been already described in CHF [2], and a negative correlation was also reported between IL-9 and left ventricular ejection fraction (LVEF) [2]. Yet, there are only limited data exploring the association between cytokines and functional capacity in CHF and their prognostic role [3]; therefore, primary end-point of the current study was to evaluate all-cause mortality according to changes in cytokines plasma levels in CHF patients.  

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathmedicineHumansInterleukin 9030212 general & internal medicineInterleukin 6CytokineInterleukin 5Risk stratificationInterleukin 4OutcomeAgedHeart Failurebiologybusiness.industryRisk FactorInterleukin-9Middle Agedmedicine.diseaseChronic heart failurePeak oxygen consumptionInterleukin 10EndocrinologyInterleukin 15Heart failurebiology.proteinCardiologyFemaleChronic heart failure; Cytokines; Interleukin-9; Outcomes; Peak oxygen consumption; Risk stratification; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular MedicinebusinessInterleukin 1 receptor type IHumanInternational journal of cardiology
researchProduct

Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective

2022

Abstract Objective Multiple sclerosis (MS) is a chronic disease with different clinical courses and a tendency to worsening. The relapsing–remitting MS presents acute onset and relapses of neurological symptoms, followed by their remission. This form can convert to secondary progressive MS (SPMS) with irreversible neurological worsening and disability. The identification of signs, symptoms, markers of progression, and strategies to manage MS patients is mandatory to allow early identification of those at higher risk of conversion to SPMS, for prompt intervention to cope with the progression of the disease. Methods A panel of Italian experts from Southern Italy have reviewed the current know…

Secondary progressive multiple sclerosis (SPMS)DermatologyGeneral MedicineBiomarkerMultiple Sclerosis Chronic ProgressiveMultiple sclerosisPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingItalyExpert opinionDiagnosisQuality of LifeDisease ProgressionHumansMultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)Neoplasm Recurrence LocalAtrophyDelivery of Health CareBiomarkersDiagnosi
researchProduct